Feb 19 (Reuters) - Cassava Sciences said on Thursday the U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam. The company said the probe ended four months after the Justice Department dismissed a criminal indictment in Maryland accusing Hoau-Yan Wang, a medical professor and former Cassava adviser who allegedly submitted false data regarding the drug.
(Reporting by Jonathan Stempel in New York, Sahil Pandey and Sriparna Roy in Bengaluru; Editing by Devika Syamnath)
